Kiora Pharmaceuticals, Inc.
KPRX
$2.48
-$0.01-0.40%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 740.90K | 890.50K | 1.17M | 1.07M | 904.60K |
| Gross Profit | -740.90K | -890.50K | -1.17M | -1.07M | -904.60K |
| SG&A Expenses | 1.38M | 1.61M | 1.46M | 1.44M | 1.35M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.12M | 2.50M | 2.63M | 2.52M | 2.26M |
| Operating Income | -2.12M | -2.50M | -2.63M | -2.52M | -2.26M |
| Income Before Tax | -2.08M | -2.42M | -7.17M | -616.30K | -2.26M |
| Income Tax Expenses | -- | -- | -650.00K | -643.10K | -112.10K |
| Earnings from Continuing Operations | -2.08M | -2.42M | -6.52M | 26.80K | -2.15M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.08M | -2.42M | -6.52M | 26.80K | -2.15M |
| EBIT | -2.12M | -2.50M | -2.63M | -2.52M | -2.26M |
| EBITDA | -2.11M | -2.49M | -2.62M | -2.50M | -2.26M |
| EPS Basic | -0.34 | -0.58 | -1.56 | 0.01 | -0.54 |
| Normalized Basic EPS | -0.20 | -0.36 | -0.37 | -0.34 | -0.33 |
| EPS Diluted | -0.34 | -0.58 | -1.56 | 0.01 | -0.54 |
| Normalized Diluted EPS | -0.20 | -0.36 | -0.37 | -0.33 | -0.33 |
| Average Basic Shares Outstanding | 6.18M | 4.17M | 4.17M | 4.29M | 3.99M |
| Average Diluted Shares Outstanding | 6.18M | 4.17M | 4.17M | 4.36M | 3.99M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |